Alaa S. Hrizat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alaa S. Hrizat has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Raymond O'NEill
Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania
2 shared publications- Robert P. Post
Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
2 shared publications - Allison Goldberg
Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
1 shared publication - Amal A. Shahin
Al-Quds University, Faculty of Medicine, Palestine
1 shared publication - Banan M Mafarjeh
Al-Quds University, Faculty of Medicine, Palestine
1 shared publication - Elena Brachtel
Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
1 shared publication
Latest Publications
- 4 July 2025
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (6) , 419-427
Exploring the efficacy of an artificial intelligence model for fungal screening in bronchoalveolar lavage cytology specimens
- 4 July 2025
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (6) , 419-427
Exploring the efficacy of an artificial intelligence model for fungal screening in bronchoalveolar lavage cytology specimens
- 6 January 2025
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (3) , 182-190
Evaluation of HER2-Low breast carcinoma in metastatic settings: a cytological approach to proliferation and survival
- 6 January 2025
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 14 (3) , 182-190
Evaluation of HER2-Low breast carcinoma in metastatic settings: a cytological approach to proliferation and survival
- Open Access
- 1 January 2025
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 28 (1) , 27-37
Association of Helicobacter pylori Infection with Pediatric Asthma in Palestine
Hrizat AS, et al. Pediatr Gastroenterol Hepatol Nutr. 2025 Jan;28(1):27-37. https://doi.org/10.5223/pghn.2025.28.1.27
- 1 January 2025
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 28 (1) , 27-37
Open AccessAssociation of Helicobacter pylori Infection with Pediatric Asthma in Palestine
Hrizat AS, et al. Pediatr Gastroenterol Hepatol Nutr. 2025 Jan;28(1):27-37. https://doi.org/10.5223/pghn.2025.28.1.27
- 12 December 2024
- Published by Elsevier in Pathology - Research and Practice
- Vol. 266, 155774
Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma
- 12 December 2024
- Published by Elsevier in Pathology - Research and Practice
- Vol. 266, 155774
Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma
- Open Access
- 14 July 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (6) , 1125-1127
Comparison of blood cell counts in leukemoid reaction and chronic myeloid leukemia: A study using Scopio blood cell counter with statistical analysis
- 14 July 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (6) , 1125-1127
Open AccessComparison of blood cell counts in leukemoid reaction and chronic myeloid leukemia: A study using Scopio blood cell counter with statistical analysis
- Open Access
- 24 December 2022
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 4 (1) , 1-14
Metastatic Breast Cancer: Cytology Diagnosis with Implications for Treatment
Breast cancer is among the most frequent malignancies in women worldwide. While early detection and effective treatment provide many women with a cure and prevent their cancer from spreading, metastases to distant sites still occur in around 20% of women suffering from breast cancer. These relapses occur in many forms and locations and are as varied as the primary breast tumors. Metastatic spread makes a cancer incurable and potentially lethal, but new, targeted treatments can offer control of the cancer cells if the features of new targets are unlocked by advanced diagnostic testing. The article offers an overview of the pathomechanisms of metastatic progression and describes the types of metastases, such as hormone-receptor-positive and -negative breast cancers, and HER2-overexpressing or triple-negative types. Once distant metastatic spread occurs, cytology allows a precise diagnosis to confirm the breast origin. Other molecular targets include ESR1 and PIK3CA mutations, MSI, NTRK fusion, PD-L1 expression and others, which can be obtained also from cytology material and used to determine eligibility for emerging targeted therapeutic options. We outline the diagnostic features of metastatic breast cancer in cytology samples, together with validated and emergent biomarkers that may provide new, targeted treatment options.
- 24 December 2022
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 4 (1) , 1-14
Open AccessMetastatic Breast Cancer: Cytology Diagnosis with Implications for Treatment
Breast cancer is among the most frequent malignancies in women worldwide. While early detection and effective treatment provide many women with a cure and prevent their cancer from spreading, metastases to distant sites still occur in around 20% of women suffering from breast cancer. These relapses occur in many forms and locations and are as varied as the primary breast tumors. Metastatic spread makes a cancer incurable and potentially lethal, but new, targeted treatments can offer control of the cancer cells if the features of new targets are unlocked by advanced diagnostic testing. The article offers an overview of the pathomechanisms of metastatic progression and describes the types of metastases, such as hormone-receptor-positive and -negative breast cancers, and HER2-overexpressing or triple-negative types. Once distant metastatic spread occurs, cytology allows a precise diagnosis to confirm the breast origin. Other molecular targets include ESR1 and PIK3CA mutations, MSI, NTRK fusion, PD-L1 expression and others, which can be obtained also from cytology material and used to determine eligibility for emerging targeted therapeutic options. We outline the diagnostic features of metastatic breast cancer in cytology samples, together with validated and emergent biomarkers that may provide new, targeted treatment options.